Prospective Evaluation of the Peptide-Bound Collagen Type I Cross-Links N-Telopeptide and C-Telopeptide in Predicting Bone Metastases Status

• DOI: 10.1200/jco.2002.20.3.850
• Publication Date: 2017-02-24T09:14:58Z
• Authors: Luis Costa; Laurence M. Demers; A. Gouveia-Oliveira; J. Schaller; Eduardo B. Costa; Miguel C. de Moura; Allan Lipton
• Keywords: N-terminal telopeptide; Bone remodeling; Type I collagen; Bone disease

The objective assessment of bone metastases is currently based on serial changes in skeletal survey. We performed a prospective study to determine whether correlation exists between the biochemical markers turnover and x-ray evaluation patients with or without bisphosphonate therapy, are influenced by extraskeletal disease.Patients either were consecutively enrolled World Health Organization response criteria applied for both extraosseous disease every 3 4 months. Serum levels bone-specific alkaline phosphatase (B-AP) C-telopeptide (ICTP) urine N-telopeptide (NTX) measured monthly. data analyzed generalized estimation equation regression.We studied 97 (52 also metastases) 26 only. Median time was 153 days, 281 evaluations (171 bone) performed. With bisphosphonates (49 receiving pamidronate three clodronate), percent change from therapy 47% NTX (P <.001) 69% B-AP =.008). progression bone, mean during stable 152% 144% ICTP regardless therapy. had highest positive predictive value (71%) diagnosis progression. Extraskeletal no significant effect markers.Urinary may be valuable marker assess antiresorptive evaluate metastases.